MARKET

PDLI

PDLI

PDL BioPharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.565
+0.025
+0.98%
Opening 15:33 12/04 EST
OPEN
2.530
PREV CLOSE
2.540
HIGH
2.570
LOW
2.520
VOLUME
718.80K
TURNOVER
--
52 WEEK HIGH
3.860
52 WEEK LOW
1.864
MARKET CAP
292.99M
P/E (TTM)
-3.5287
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)
Benzinga · 11/12 12:44
Recap: PDL BioPharma Q3 Earnings
Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were down 211.11% year over year to ($0.10), which missed the estimate of $0.06.Revenue of $4,115,000 declined by 90.68% from the same period last year,
Benzinga · 11/11 21:34
PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
, /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended and provides an update on important milestones achieved in the execution of its monetization and liquidation plan.
PR Newswire - PRF · 11/11 21:05
PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and provides an update on important milestones achieved in the execution of its monetization and liquidation plan.
PR Newswire · 11/11 21:05
PDL BioPharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 11, 2020 / PDL BioPharma, Inc. (NASDAQ:PDLI) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 11, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 11/11 19:31
PDL BioPharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 9, 2020 / PDL BioPharma, Inc.
ACCESSWIRE · 11/09 19:30
LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update
--Cash and Cash Equivalents of $42.7 Million as of September 30, 2020
BusinessWire · 11/09 18:01
PDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business Update
, /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference call to , 2020.  PDL will issue its third quarter 2020 financial results news release on after market close, and PDL's management will host a conference call and webcast that same day at to discuss those financial results and provide an update on its progress in monetizing the Company's assets.  A slide presentation to accompany the call will be available via the webcast link on the PDL website at .
PR Newswire - PRF · 11/06 22:27
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PDLI. Analyze the recent business situations of PDL BioPharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PDLI stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 229
Institutional Holdings: 107.01M
% Owned: 93.69%
Shares Outstanding: 114.23M
TypeInstitutionsShares
Increased
29
7.16M
New
49
5.71M
Decreased
49
10.09M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.52%
Pharmaceuticals & Medical Research
+1.47%
Key Executives
Chairman/Director
Elizabeth O Farrell
Chairman/Director
Elizabeth O'Farrell
President/Chief Executive Officer/Director
Dominique Monnet
Chief Accounting Officer/Vice President - Finance
Ed Imbrogno
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
Edward Imbrogno
Vice President/General Counsel/Secretary
Christopher Stone
Director
John McLaughlin
Independent Director
Alan Bazaar
Independent Director
David Gryska
Independent Director
Natasha Hernday
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
05/02/2016
Dividend USD 0.05
06/02/2016
01/26/2016
Dividend USD 0.05
03/02/2016
01/27/2015
Dividend USD 0.15
12/02/2015
01/27/2015
Dividend USD 0.15
09/02/2015
01/27/2015
Dividend USD 0.15
06/03/2015
01/27/2015
Dividend USD 0.15
03/03/2015
01/29/2014
Dividend USD 0.15
12/03/2014
01/29/2014
Dividend USD 0.15
09/03/2014
01/29/2014
Dividend USD 0.15
06/03/2014
01/29/2014
Dividend USD 0.15
03/03/2014
01/23/2013
Dividend USD 0.15
12/03/2013
01/23/2013
Dividend USD 0.15
09/03/2013
01/23/2013
Dividend USD 0.15
06/03/2013
01/23/2013
Dividend USD 0.15
03/01/2013
01/18/2012
Dividend USD 0.15
12/05/2012
01/18/2012
Dividend USD 0.15
09/05/2012
01/18/2012
Dividend USD 0.15
06/05/2012
01/18/2012
Dividend USD 0.15
03/05/2012
02/25/2011
Dividend USD 0.15
12/06/2011
02/25/2011
Dividend USD 0.15
09/06/2011
02/25/2011
Dividend USD 0.15
06/06/2011
02/25/2011
Dividend USD 0.15
03/04/2011
01/26/2010
Dividend USD 0.5
09/13/2010
01/26/2010
Dividend USD 0.5
03/11/2010
11/11/2009
Dividend USD 1.67
11/27/2009
03/02/2009
Dividend USD 0.5
09/15/2009
03/02/2009
Dividend USD 0.5
03/12/2009
04/09/2008
Dividend USD 4.25
05/06/2008
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PDLI
PDL BioPharma, Inc. has a portfolio of income generating assets based on alternative financings. These alternative financings fall into one of three categories: royalty monetization, debt structures and hybrids of the two. The Company's investments are typically in assets with strong intellectual property protection and are commercial stage or soon-to-be approved. The counterparties in these transactions can be biotechs, pharmas, medtech companies, universities and inventors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of PDL BioPharma Inc stock information, including NASDAQ:PDLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDLI stock methods without spending real money on the virtual paper trading platform.